With new emerging biomarkers and new technologies, the practice of pathology is growing and changing daily. We are committed to providing pathologists with up-to-date information, education and training that will advance your knowledge and elevate your confidence in results. This portal provides the tools you need to explore and understand the newest horizons of pathology, including companion diagnostics, immunotherapy, and biomarker and disease state information. Below, find access to educational modules, cutting-edge research articles, and more.
Our dedicated team of in-house pathologists has developed a variety of educational modules, including videos and interactive courses, to aid in the interpretation of our assays. Access these modules, along with cutting-edge research articles and more, below.
A comprehensive interactive training course for the only CE marked Companion Diagnostics ALK IHC binary assay for NSCLC. The course is designed for Pathologists and other professional users to provide background, science and interpretation of the VENTANA ALK (D5F3) Rabbit Monoclonal Primary Antibody (Ventana ALK (D5F3) Assay) for use in the evaluation of NSCLC.
Over the sequential four modules, the user will learn how to assess the staining and interpretation of the VENTANA ALK (D5F3) Assay and concludes with a proficiency test. A certificate is offered to those who successfully complete the course.
Course completion time: 2-3 hours
This course consists of three high-impact topic videos, covering the role of hyaluronan (HA) as a biomarker; specifically, the interaction of the tumour micro-environment and hyaluronan. It also provides training on targeting HA using a novel, affinity histochemistry based assay and assessing HA content in GI and non-GI tissue types.
Stay at the forefront of predictive diagnostics and make a positive impact on patient care. This a series of focused, interactive courses was developed to aid the scoring and interpretation of VENTANA PD-L1 (SP142) Assay and VENTANA PD-L1 (SP263) Assay to target those patients who are more likely to respond to specific therapies.